Takeda Issues Voluntary Product Withdrawal

medical supplies

Takeda today announced that it is conducting a voluntary market withdrawal for two product lots of 650 IU VONVENDI® [von Willebrand factor] in the U.S. Takeda announced that the withdrawal is being conducted out of an abundance of caution due to misprinted product labels with the incorrect expiration date. The expiration date printed on the […]

HFA Announcement to Community and Industry Partners

In response to the ever-evolving landscape and the need to adapt to new challenges, the Hemophilia Federation of America Board of Directors and staff are undertaking an organizational restructure.  As part of this process, there will be some necessary staff adjustments, including a reduction in force. While these decisions are never easy, they are essential […]

Statement: HFA and NBDF Address WHO Recommendations

infusion

Hemophilia Federation of America (HFA) and the National Bleeding Disorders Foundation (NBDF) are deeply concerned by the World Health Organization’s (WHO) recommendation of cryoprecipitate (pathogen-reduced and non-pathogen-reduced) in the 23rd Essential Medicines List (EML) for treatment for hemophilia.   With FVIII concentrates available globally, the inclusion of cryoprecipitate as treatment for hemophilia is an egregious, misguided […]

HFA Project Featured in International, Peer-Reviewed Scientific Journal

DNA strand

Hemophilia Federation of America is excited to announce its work encouraging patient-centered research for females with bleeding disorders, conducted by members of its staff as well as trusted medical advisors in the bleeding disorders community, has been published in the international, peer-reviewed scientific journal Haemophilia. “Females+ with bleeding symptoms or a diagnosis of a bleeding […]

Blog: Intern Introspective #7

Capitol rooftoop

It feels incredibly surreal to think about the fact that this is my final week at HFA this summer, and that in less than a week I will no longer be exploring D.C. and will instead be back home in San Diego. The past ten weeks here in Washington, D.C. with HFA have been an […]

Blog: Intern Introspective #6

Capitol rooftoop

The fact that I only have two months of interning this summer here in Washington, D.C. has led me to jam-pack my days full in a desperate attempt to make the most of this incredible opportunity. My weekdays always start with me hopping in the shower (shower count: 1) before I quickly cook myself a […]

Blog: Intern Introspective #5

Capitol rooftoop

Last week, HFA held the Young Adult Advocacy Summit, or as we called it in-office, YAAS. Saturday’s evening began with a lovely introduction to all those who were flown in, and Noemy and I were quickly welcomed into the fold of young adults who were either bleeders or siblings of bleeders, just like myself. Being […]

Blog: Intern Introspective #4

Capitol rooftoop

A Day-in-the-Life of an HFA Intern: Greetings from the nation’s capital! As we reach the halfway point of my internship at HFA, I would say that I have found my rhythm in D.C. Although I have been in the district since late April for a previous internship, the way I prepare for a day in […]

Statement: HFA Responds to Latest Gene Therapy Announcement

DNA strand

Yesterday, the U.S. Food and Drug Administration approved Roctavian (valoctocogene roxaparvovec), the first gene therapy for hemophilia A. This new treatment option, for the treatment of adults with severe factor VIII deficiency, represents a significant milestone in the treatment of hemophilia A.    As a community-based, patient-centered organization, Hemophilia Federation of America (HFA) intimately understands and […]

Blog: Intern Introspective #3

Capitol rooftoop

No matter how many times I visit Capitol Hill, there is always a larger-than-life sensation I get whenever I see the buildings looming over me. I think it’s the knowledge that these people who know next to nothing about my life experience have my livelihood in their hands. The immense power held by this small […]

en_USEnglish